Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis
PRINCETON, N.J., Dec. 19, 2022. Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 19, 2022 Category: Pharmaceuticals Source Type: clinical trials
Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial
DiscussionThe CAMARO trial investigates whether treatment with MMF and prednisolone increases the proportion of patients in remission compared with azathioprine and prednisolone as the current standard treatment strategy. In addition, we reflect on the challenges of conducting a randomized trial in rare diseases.Trial registrationEudraCT2016-001038-91. Prospectively registered on 18 April 2016.Graphical Abstract (Source: Trials)
Source: Trials - December 13, 2022 Category: Research Source Type: clinical trials
CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherapy
ARCADIA, Calif., Nov. 16, 2022. Theragent, a cell therapy Contract Development and Manufacturing Organization (CDMO) focused on advancing next-generation cancer and rare disease treatments, has announced that they have been selected by CellVax... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 16, 2022 Category: Pharmaceuticals Source Type: clinical trials
Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer
TAIPEI and SAN DIEGO, Oct. 31, 2022. Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that their first patient has been... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 31, 2022 Category: Pharmaceuticals Source Type: clinical trials
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Conditions: Inherited Retinal Degeneration; Retinitis Pigmentosa Intervention: Sponsors: Jaeb Center for Health Research; Foundation Fighting Blindness Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2022 Category: Research Source Type: clinical trials
